Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Vaccinations

Vaccinations

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

CD19/CD22 bivalent CAR T cells in children, adolescents and young adults with B-ALL: final phase 1 trial results.

Journal for immunotherapy of cancer·2026

Same author

Distinct in vivo dynamics of donor-derived stem cell memory CAR T cells post-allogeneic HSCT relapse.

Cell·2026

Same author

Bringing in vivo CAR to the clinic: Promise, pitfalls, and questions to ask.

Molecular therapy : the journal of the American Society of Gene Therapy·2026

Same author

A multicentre analysis of efficacy, safety and molecular response correlates of fostamatinib in warm autoimmune haemolytic anaemia and Evans syndrome.

British journal of haematology·2026

Same author

Assessing T-cell responses to Epstein-Barr virus in individuals at risk for nasopharyngeal carcinoma.

Infectious agents and cancer·2026

Same author

Alpha-gal sensitization and allergic blood transfusion reactions: a scoping review.

Journal of translational medicine·2026

Search research articles

Related Experiment Video

Updated: May 8, 2025

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

Dendritic Cell Cancer Vaccines: A Focused Review.

Hoyoung M Maeng¹, Purevdorj B Olkhanud², Mary Black³

¹Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. hoyoung.maeng@nih.gov.

Methods in Molecular Biology (Clifton, N.J.)

|April 23, 2025

Summary

Dendritic cell (DC) cancer vaccines, grown ex vivo, can overcome tumor-induced immune suppression. These vaccines, combined with therapies blocking immunosuppression, show promise for treating "cold" tumors and enhancing anti-cancer immunity.

Keywords:

Cancer immunotherapy Cancer vaccines Clinical trials Dendritic cells Murine models

More Related Videos

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

Isolation Protocol of Mouse Monocyte-derived Dendritic Cells and Their Subsequent In Vitro Activation with Tumor Immune Complexes

Isolation Protocol of Mouse Monocyte-derived Dendritic Cells and Their Subsequent In Vitro Activation with Tumor Immune Complexes

Published on: May 31, 2018

Related Experiment Videos

Last Updated: May 8, 2025

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

Isolation Protocol of Mouse Monocyte-derived Dendritic Cells and Their Subsequent In Vitro Activation with Tumor Immune Complexes

Isolation Protocol of Mouse Monocyte-derived Dendritic Cells and Their Subsequent In Vitro Activation with Tumor Immune Complexes

Published on: May 31, 2018

Area of Science:

Immunology
Oncology
Cell Therapy

Background:

Dendritic cells (DCs) are potent antigen-presenting cells crucial for T cell activation.
Tumors can suppress DC development and maturation, hindering anti-cancer immune responses.
Ex vivo engineered DC vaccines offer a strategy to overcome tumor-induced immunosuppression.

Purpose of the Study:

To explore the potential of ex vivo generated dendritic cell (DC) cancer vaccines.
To investigate the synergistic effects of DC vaccines with immunomodulatory therapies.
To enhance anti-cancer immunity, particularly for tumors resistant to current treatments.

Main Methods:

Generating and maturing dendritic cells (DCs) ex vivo from precursor cells.
Loading DCs with tumor antigens via synthetic peptides or viral transduction.
Administering autologous DCs as a cancer vaccine.
Combining DC vaccination with therapies that block immunosuppressive mechanisms.

Main Results:

Ex vivo generated DCs show promising immunogenicity in early clinical trials.
DC vaccines can induce immune responses in "cold" tumors unresponsive to other therapies.
Combining DC vaccines with immunosuppression blockade is expected to synergize for optimal anti-cancer effects.

Conclusions:

Engineered dendritic cell (DC) cancer vaccines represent a viable strategy to overcome tumor-induced immune suppression.
The combination of DC vaccines and immunosuppression blockade holds significant potential for treating various cancers, including "cold" tumors.
This combined approach aims to optimize anti-cancer immune responses for tumor rejection, akin to allogeneic transplant rejection.